Remember meForgot password?
    Log in with Twitter
Press Release

Global Type 1 Diabetes Drugs Market to Grow at a CAGR of 8.05% During the Period 2016 - 2020; Finds New Report

Market Research Reports, Inc. has announced the addition of “Global Type 1 Diabetes Market 2016 - 2020” research report to their website

This press release was orginally distributed by SBWire

Lewes, DE -- (SBWIRE) -- 04/04/2016 -- Report forecast the global type 1 diabetes drugs market to grow at a CAGR of 8.05% during the period 2016-2020.

Diabetes, often referred to as diabetes mellitus, results in high blood glucose levels. Depending on the cause of development, it can be divided into three types:
- Type 1 diabetes (or insulin-dependent diabetes mellitus): The pancreas do not produce the required amount of insulin in the body, leading to high blood glucose levels.
- Type 2 diabetes (non-insulin-dependent diabetes mellitus): In this condition, though the body produces the required amount of insulin, the cells do not respond to it. This results in a high glucose level in the body.
- Gestational diabetes: This condition occurs in pregnant women without any history of diabetes.

Type 1 diabetes is an autoimmune disorder characterized by high blood glucose levels. In this condition, the immune system is activated against insulin-producing cells. This condition hampers the body's ability to produce insulin and disrupts blood glucose homeostasis.

Type 1 diabetes differs from a more prevalent form of diabetes mellitus, type 2 diabetes, wherein the insulin is produced inside the body. Type 1 diabetes accounts for only 5%-15% of the total diabetes cases. As the disease is more prevalent among children and adolescents aged 0-15 years, it was earlier known as juvenile diabetes. Type 1 diabetes management relies on providing symptomatic relief and improving the quality of life of people.

The report covers the present scenario and the growth prospects of the global type 1 diabetes drugs market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded drugs and biosimilars used to treat and prevent type 1 diabetes.

The market is divided into the following segments based on geography:
- Americas

According to the report, an increase in the type 1 diabetes population is expected to increase the number of people opting for treatment. This will drive the sale and revenue of these drugs. The market for type 1 diabetes drugs is served by insulin-based replacement products, including regular insulin and insulin analogs. Chemically, insulin-based products can be categorized into animal insulin, recombinant human insulin, and insulin analogs.

Further, the report states that besides the high prices and accessibility of insulin-based therapies, the products also have poor storage and distribution policies. Inadequate distribution policies and the lack of a centralized supply chain lead to price variations between countries.

Global Type 1 Diabetes Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

key players in the Global Type 1 Diabetes Drugs Market: Eli Lilly and Company, Novo Nordisk A/S, and Sanofi SA.

Other Prominent Vendors in the market are: Adocia, Astellas Pharma, AstraZeneca, Baxalta, BHV Pharma, Biocon, Biodel, Boehringer Ingelheim, CureDM, Dance Biopharm, Diamyd Therapeutics AB, Diasome Pharmaceuticals, DiaVac, Exsulin, Gan & Lee Pharmaceuticals, Generex Biotechnology, GlaxoSmithKline, ILTOO Pharma, Intrexon, Islet Sciences, Kamada, Kotobuki Pharmaceutical, Lexicon Pharmaceuticals, Living Cell Technologie, MacroGenics, MannKind Pharmaceuticals, Merck, Merrion Pharmaceutical, Oramed Pharmaceuticals, Osiris Therapeutics, Perle Biosciences, Pfizer, REGiMMUNE, Strongbridge Biopharma, Toleranzia, Tolerio, Xeris Pharmaceuticals, and XOMA.

Market driver
- Increase in prevalence of type 1 diabetes
- For a full, detailed list, view our report

Market challenge
- Poor storage conditions and distribution policies for insulin
- For a full, detailed list, view our report

Market trend
- Awareness programs and initiatives
- For a full, detailed list, view our report

Key questions answered in this report
- What will the market size be in 2020 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

Spanning over 80 pages and 44 Exhibit "Global Type 1 Diabetes Market 2016 – 2020" report covers Executive summary, Scope of the report, Market research methodology, Introduction, Market landscape, Disease overview, Insulin: An overview, Pipeline analysis, Reimbursement scenario in US, Market segmentation by drug class, Geographical segmentation, Market drivers, Impact of drivers, Market challenges, Impact of drivers and challenges, Market trends, Vendor landscape, Appendix.

For more information Visit at:

Related Report;

Global Type 2 Diabetes Market 2016-2020 - Visit at -

Find all IT and eHealth report at :

About Market Research Reports, Inc.
Market Research Reports, Inc. is the world's leading source for market research reports and market data. We provide you with the latest market research reports on global markets, key industries, leading companies, new products and latest industry analysis & trends.

Yearly/Quarterly Report Subscription:

For more information on this press release visit:

Media Relations Contact

Sudeep Chakravarty
GM - Operations
Market Research Reports, Inc.
Telephone: 302-703-7787
Email: Click to Email Sudeep Chakravarty

Latest News
Top News